Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medtronic, St. Jude Launch New Quadripolar Devices

This article was originally published in The Gray Sheet

Executive Summary

Medtronic has launched two more Attain Performa left ventricular quadripolar leads for the Viva Quad XT and Viva Quad S cardiac resynchronization therapy defibrillators following FDA approval announced Dec. 11. On the same day, St. Jude announced CE mark of the Quadra Allure MP cardiac resynchronization therapy pacemaker, the first quadripolar CRT-P with MultiPoint pacing.

You may also be interested in...



HRS In Brief

Data highlighted earlier this month at the Heart Rhythm Society annual conference in Boston include results for new ablation systems, quadripolar leads and antibacterial cardiac implant wraps.

New Product Briefs: Medtronic CRT-D; Syncardia Valve; Lombard AAA Graft

Medtronic is set for the U.S. launch of the Viva Quad XT and Viva Quad S cardiac resynchronization devices. Syncardia earns FDA approval for a new propriety valve set for its total artificial heart. Lombard earns Japanese approval for its AAA graft. Philips announces a unique case in Canada.

St. Jude Medical: Cardiac Rhythm Management Business Has “Turned The Corner”

The firm reported during its second-quarter earnings call that its cardiac rhythm management business has stabilized after several quarters of market share decline.

Related Content

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT033578

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel